Ascendis Pharma A/S has two approved products and plans to submit a third drug candidate for approval later this year from its endocrinology rare disease portfolio. It also has two clinical-stage can
Venture capital fundraising by biopharmaceutical firms in the second quarter was a mixed bag, according to Venture Monitor data from Pitchbook and the National Venture Capital Association (NVCA), wh